Chattem R&D
This article was originally published in The Rose Sheet
Executive Summary
Health and beauty aids manufacturer will break ground for $2 mil., 10,000 sq.-ft. research and development facility in Chattanooga, Tenn. in February, company announces. Research facility, which is slated for completion by end of calendar year, will be dedicated to creating line extensions for existing products, according to President, Chief Operating Officer Alec Taylor. Gold Bond sales are expected to be $40 mil.- $42 mil. in 2002, and pHisoderm annual sales are expected to be in $15 mil.-$17 mil. range, Taylor reports during 1presentation at Banc of America Securities Equity and High Yield Research Household Products Conference Jan. 10...
You may also be interested in...
Chattem Gold Bond, pHisoderm Extensions To Launch In Coming Months
Chattem is gearing up to launch a slew of new product line extensions within the next few months as its decision to increase its investment in R&D over the past two years begins to pay dividends
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.